Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Psoriatic arthritis is an inflammatory autoimmune disease wherein the immune system of the body identifies its own skin cells as a foreign entity and starts to attack it. Psoriatic arthritis causes inflammation of joints and entheses, the place where the ligaments or tendons are connected to the bone. The inflammation of entheses is termed as Enthesitis and can be seen at the bottom of feet, Achilles tendons, pelvis, ribs, and spine. If untreated, enthesitis may lead to calcification or fibrosis of tissues. Psoriatic arthritis in the spine is known as psoriatic spondylitis which may cause swelling and stiffness in areas such as lower back, spinal vertebrae, pelvic, neck, and others. Spondylitis can cause inflammation in ligaments and joints of arms, hips, feet, legs, and others. Psoriatic arthritis may also cause inflammation of fingers and toe in an asymmetrical manner. This inflammatory condition is termed as Dactylitis or sausage digits. The severity of psoriatic arthritis can range from mild to severe. Oligoarticular psoriatic arthritis is a milder type of psoriatic arthritis wherein, up to four joints are affected while polyarticular psoriatic arthritis is a more severe type wherein, more than four joints are affected.

The global psoriatic arthritis treatment market is estimated to be valued at US$ 10,100.9 million in 2021 and is expected to exhibit a CAGR of 8.4% over the forecast period (2021-2028).

Figure 1. Global Psoriatic Arthritis Treatment Market Share (%), By Region, 2021

Psoriatic Arthritis Treatment  | Coherent Market Insights

The increasing incidence of psoriatic arthritis and psoriasis is expected to drive the growth of the global psoriatic arthritis treatment market over the forecast period.

For instance, according to a review article published by the Clinical and Experimental Rheumatology in March 2019, the prevalence of psoriatic arthritis was estimated to be around 1/100,000 people in Japan and 420/100,000 people in Italy in 2019.

request-sample

Psoriatic Arthritis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 10,100.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 8.4% 2028 Value Projection: US$ 17,765.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: NSAIDs (Non-steroidal Anti-inflammatory Drugs, DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs), Biologics, Others (Others include Immunosuppressant, Enzyme Inhibitor and Interleukin Inhibitors)
  • By Disease Type: Asymmetric Psoriatic Arthritis, Symmetric Psoriatic Arthritis, Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis, Psoriatic Spondylitis, Psoriatic Arthritis Mutilans
  • By Drug Type: Prescriptions, Over-the-counter
  • By Route of Administration: Topical, Oral, Injectable
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Amgen Inc., Sanofi S.A., Johnson & Johnson Services, Inc., Novartis International AG, AstraZeneca, Bausch Health Companies Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer, Inc., UCB S.A., Sun Pharma Global FZE, AltruBio, Merck & Co Inc., and Celgene Corporation

Growth Drivers:
  • Increasing prevalence of psoriasis and psoriatic arthritis
  • Increasing products approval and launches
Restraints & Challenges:
  • High cost of psoriatic arthritis drugs
  • Adverse effects of psoriatic arthritis drugs

Figure 2. Global Psoriatic Arthritis Treatment Market Value (US$ Mn), By Drug Class, 2021

Psoriatic Arthritis Treatment  | Coherent Market Insights

The increasing research and development activities for the development of novel therapeutics for the treatment of psoriatic arthritis is expected to drive the market growth over the forecast period.

Key players operating in the market are focusing on submitting application for approval of drugs for the treatment of psoriatic arthritis, which is expected to drive the growth of the global psoriatic arthritis treatment market over the forecast period.

For instance, in April 2021, AbbVie Inc., a U.S.-based biopharmaceutical company, announced that the company had submitted Biologics License Application to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in order to seek approval for its drug SKYRIZI. SKYRIZI is an interleukin inhibitor which can be used for the treatment of active psoriatic arthritis in adults.

Moreover, according to ClinicalTrials.gov, a Phase 3 clinical trial study was initiated by AbbVie Inc. in March 2019 to determine the potential use of its drug Risankizumab (SKYRIZI) in patients suffering from active psoriatic arthritis who are intolerant to biologic therapy or non-biologic disease-modifying anti-rheumatic drugs (DMARDs). The Phase 3 results of SKYRIZI show that the drug is safe and effective to be used for the treatment of active psoriatic arthritis in adults.

Global Psoriatic Arthritis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) emerged from Wuhan, China in December 2019 and was declared a global pandemic by the World Health Organization (WHO) in January 2020. According to the World Health Organization weekly COVID-19 update published on August 25, 2021 COVID-19 has spread across the globe infecting over 211 million population leading to more than 4.4million deaths. The impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industry’s entire supply chain, from raw materials to manufacturing and delivery. Similarly, COVID-19 pandemic is expected to hamper the overall growth of global psoriatic arthritis treatment market during the pandemic.

However, in some cases psoriatic arthritis has been seen to be associated with COVID-19 infection and this is expected to show growth in the global psoriatic arthritis treatment market during the pandemic. For instance, according to an article published in the Oxford University Press Public Health Emergency Collection Journal in November 2020, Humanitas Clinical and Research Center in Milan had reported the first COVID-19 triggered psoriatic arthritis case of a 27-year old woman who has developed spondyloarthritis simultaneously with COVID-19 infection.

Global Psoriatic Arthritis Treatment Market: Restraint

The high cost and adverse effects of drugs used in the treatment of psoriatic arthritis are the factors that are expected to hinder the growth of the global psoriatic arthritis treatment market over the forecast period. For instance, according to a Brazilian study published by the Frontiers of Pharmacology Journal in September 2019, around 25% people showed severe adverse effects while around 43.3% people showed at least one adverse reaction associated with biologics used for the treatment of psoriatic arthritis and rheumatoid arthritis.

Key Players

Major players operating in the global psoriatic arthritis treatment market include AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Amgen Inc., Sanofi S.A., Johnson & Johnson Services, Inc., Novartis International AG, AstraZeneca, Bausch Health Companies Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, , Eli Lilly and Company, Pfizer, Inc., UCB S.A., Sun Pharma Global FZE, AltruBio, Merck & Co Inc., and Celgene Corporation

Psoriatic arthritis is one of the types of inflammatory arthritis that occurs in some people suffering from psoriasis, a skin condition wherein red, scaly patches appear on the skin. Usually, psoriasis is followed by psoriatic arthritis, however, pain in joints may start even before any patches are visible on the skin of the patient. Some of the symptoms associated with psoriatic arthritis include pain, swelling, and stiffness in joints. Painful, swelling of fingers and toes can be observed in patients suffering from psoriatic arthritis. Some people suffer from spondylitis caused due to psoriatic arthritis. In spondylitis, inflammation of joints between vertebrae and spine occurs along with inflammation in joints between spine and pelvis. Some of the factors that increase the risk of psoriatic arthritis include age, genetics, and having psoriasis. Psoriatic arthritis is incurable, thus it is important to manage its symptoms using available therapeutic drugs related to psoriatic arthritis. This is expected to drive the growth of psoriatic arthritis market.

Market Dynamics

The increasing incidence of psoriasis and psoriatic arthritis, rising research and development activities for the development of novel therapeutics for the treatment of psoriatic arthritis, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive the growth of the global psoriatic arthritis treatment market over the forecast period.

For instance, according to a review article by Seminars in Arthritis and Rheumatism Journal published in August 2018, the global prevalence of psoriatic arthritis was estimated to be 133 every 100,000 people in 2018.

Key features of the study:

  • This report provides in-depth analysis of the global psoriatic arthritis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global psoriatic arthritis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Amgen Inc., Sanofi S.A., Johnson & Johnson Services, Inc., Novartis International AG, AstraZeneca, Bausch Health Companies Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer, Inc., UCB S.A., Sun Pharma Global FZE, AltruBio, Merck & Co Inc., and Celgene Corporation
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global psoriatic arthritis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global psoriatic arthritis treatment market

Detailed Segmentation:

  • Global Psoriatic Arthritis Treatment Market, By Drug Class:
    • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
    • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
    • Biologics
    • Others (Others includes Immunosuppressant, Enzyme Inhibitor, and Interleukin Inhibitors)
  • Global Psoriatic Arthritis Treatment Market, By Disease Type:
    • Asymmetric Psoriatic Arthritis
    • Symmetric Psoriatic Arthritis
    • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
    • Psoriatic Spondylitis
    • Psoriatic Arthritis Mutilans
  • Global Psoriatic Arthritis Treatment Market, By Drug Type:
    • Prescriptions
    • Over-the-counter
  • Global Psoriatic Arthritis Treatment Market, By Route of Administration:
    • Topical
    • Oral
    • Injectable
  • Global Psoriatic Arthritis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Psoriatic Arthritis Treatment Market, By Region:
    • North America
      • By Drug Class
        • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
        • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
        • Biologics
        • Others (Others includes Immunosuppressant, Enzyme Inhibitor and Interleukin Inhibitors)
      • By Disease Type
        • Asymmetric Psoriatic Arthritis
        • Symmetric Psoriatic Arthritis
        • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
        • Psoriatic Spondylitis
        • Psoriatic Arthritis Mutilans
      • By Drug Type
        • Prescriptions
        • Over-the-counter
      • By Route of Administration
        • Topical
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class
        • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
        • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
        • Biologics
        • Others (Others includes Immunosuppressant, Enzyme Inhibitor, and Interleukin Inhibitors)
      • By Disease Type
        • Asymmetric Psoriatic Arthritis
        • Symmetric Psoriatic Arthritis
        • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
        • Psoriatic Spondylitis
        • Psoriatic Arthritis Mutilans
      • By Drug Type
        • Prescriptions
        • Over-the-counter
      • By Route of Administration
        • Topical
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
        • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
        • Biologics
        • Others (Others includes Immunosuppressant, Enzyme Inhibitor, and Interleukin Inhibitors)
      • By Disease Type
        • Asymmetric Psoriatic Arthritis
        • Symmetric Psoriatic Arthritis
        • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
        • Psoriatic Spondylitis
        • Psoriatic Arthritis Mutilans
      • By Drug Type
        • Prescriptions
        • Over-the-counter
      • By Route of Administration
        • Topical
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
        • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
        • Biologics
        • Others (Others includes Immunosuppressant, Enzyme Inhibitor and Interleukin Inhibitors)
      • By Disease Type
        • Asymmetric Psoriatic Arthritis
        • Symmetric Psoriatic Arthritis
        • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
        • Psoriatic Spondylitis
        • Psoriatic Arthritis Mutilans
      • By Drug Type
        • Prescriptions
        • Over-the-counter
      • By Route of Administration
        • Topical
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
        • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
        • Biologics
        • Others (Others includes Immunosuppressant, Enzyme Inhibitor and Interleukin Inhibitors)
      • By Disease Type
        • Asymmetric Psoriatic Arthritis
        • Symmetric Psoriatic Arthritis
        • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
        • Psoriatic Spondylitis
        • Psoriatic Arthritis Mutilans
      • By Drug Type
        • Prescriptions
        • Over-the-counter
      • By Route of Administration
        • Topical
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
        • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
        • Biologics
        • Others (Others includes Immunosuppressant, Enzyme Inhibitor and Interleukin Inhibitors)
      • By Disease Type
        • Asymmetric Psoriatic Arthritis
        • Symmetric Psoriatic Arthritis
        • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
        • Psoriatic Spondylitis
        • Psoriatic Arthritis Mutilans
      • By Drug Type
        • Prescriptions
        • Over-the-counter
      • By Route of Administration
        • Topical
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AbbVie Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Otsuka Pharmaceutical Co., Ltd.
    • Amgen Inc.
    • Sanofi S.A.
    • Johnson & Johnson Services, Inc.
    • Novartis International AG
    • AstraZeneca
    • Bausch Health Companies Inc.
    • Janssen Biotech, Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Pfizer, Inc.
    • UCB S.A.
    • Sun Pharma Global FZE
    • AltruBio
    • Merck & Co Inc.
    • Celgene Corporation

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Disease Type
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Highlights
    • Reimbursement Scenario
    • Mergers & Acquisitions
  4. Global Psoriatic Arthritis Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Psoriatic Arthritis Treatment Market, By Drug Class, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • NSAIDs (Non-steroidal Anti-inflammatory Drugs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • DMARD (Non-biologic Disease Modifying Anti-Rheumatic Drugs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Biologics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others (Others includes Immunosuppressant, Enzyme Inhibitor, and Interleukin Inhibitors)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Psoriatic Arthritis Treatment Market, By Disease Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Asymmetric Psoriatic Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Symmetric Psoriatic Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Psoriatic Spondylitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Psoriatic Arthritis Mutilans
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Psoriatic Arthritis Treatment Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Prescriptions
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Over-the-counter
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  8. Global Psoriatic Arthritis Treatment Market, By Route of Administration, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  9. Global Psoriatic Arthritis Treatment Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  10. Global Psoriatic Arthritis Treatment Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  11. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Otsuka Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson Services, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Janssen Biotech, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • UCB S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sun Pharma Global FZE
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AltruBio
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  12. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 40 market data tables and 32 figures on "Psoriatic Arthritis Treatment Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global psoriatic arthritis treatment market size is estimated to be valued at US$ 10,100.9 million in 2021 and is expected to exhibit a CAGR of 8.4% between 2021 and 2028.
Increasing incidence of psoriatic arthritis and increasing research and development activities for the development of novel therapeutics for the treatment of psoriatic arthritis are expected to drive the market growth over the forecast period.
Biologics segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering the growth of the market include the high cost and adverse effects of psoriatic arthritis drugs.
Major players operating in the market include AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Amgen Inc., Sanofi S.A., Johnson & Johnson Services, Inc., Novartis International AG, AstraZeneca, Bausch Health Companies Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer, Inc., UCB S.A., Sun Pharma Global FZE, AltruBio, Merck & Co Inc., and Celgene Corporation
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.